Close Menu

NEW YORK – Daiichi Sankyo said on Wednesday that it has dosed the first triple-negative breast cancer patient in a Phase I study evaluating the investigational agent DS-1062.

The TROP2-directed DXd antibody-drug conjugate previously demonstrated encouraging efficacy in non-small cell lung cancer patients. Based on that, Daiichi Sankyo expanded the study to include TNBC patients, who lack treatment options since their tumors lack expression of HER2, estrogen, and progesterone receptors. However, up to 80 percent of TNBC patients have high TROP2 expression.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.


Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.


Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.


This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.